Novo Nordisk or Eli Lilly: First GLP-1 cardiovascular drug ad campaign in 2026: Both in 2026

Voided · refunded

Volume: 155 SP
Holders: 0
Closes: Apr 1, 2027

Resolution

Rule

This market resolves YES if a GLP-1 receptor agonist receives FDA approval for an additional cardiovascular indication between January 1, 2026 and December 31, 2026. Source: FDA approval announcements or official FDA.gov drug approvals database. If multiple GLP-1s receive cardiovascular indication approvals in 2026, this market resolves YES upon the first approval date.

Source: https://www.fda.gov/

Resolves by Apr 8, 2027.

Discussion

4 comments

@lucybrooksLucy Brooks2 days ago
ozempic already doing the heavy lifting for pharma, why rush another indication when the money's already there.
- @irisbrooks2 days ago
  ozempic's printing money but pharma always stacks indications once they smell blood in the water, and cardio's the biggest prize left.
@haydeningramHayden Ingram2 days ago
glp-1 cardio approval in 2026 feels like the thing that actually moves retail demand, not the weight loss story.
@sofiadiazSofia Diaz27 days ago
agreed.